VIP (Vasoactive Intestinal Peptide) (10mg)
VIP is a 28-amino acid neuropeptide with anti-inflammatory and immunomodulatory properties. Reconstitute with 2mL of bacteriostatic water for 5mg/mL. Administered subcutaneously.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full VIP encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
VIP acts via VPAC1/VPAC2 receptors, reducing inflammatory cytokines (TNF-α, IL-6), regulating T-regulatory cells, and improving pulmonary function. It promotes vasodilation and regulates circadian rhythm.
Quick Start
- Reconstitution: Add 2.0 mL of BAC water → 5.0 mg/mL.
- Typical dose: 25–50 mcg subcutaneously, 1–2×/day.
- Storage: −20 °C (powder); 2–8 °C (solution), use within 14 days.
Dosing Table — VIP 10mg (Subcutaneous)
Route: Subcutaneous | Frequency: 1–2× daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 25 mcg / dose | 0.5 Units (0.01 mL) |
| Weeks 3–4 | 50 mcg / dose | 1 Units (0.01 mL) |
| Weeks 5+ | 50 mcg / dose | 1 Units (0.01 mL) |
Start low due to risk of hypotension. Increase gradually. Use under medical guidance—this is a particularly sensitive peptide.
Related compounds
Reconstitution Steps
- Wipe the vial stoppers with an alcohol swab.
- Draw up 2.0 mL of bacteriostatic water.
- Slowly inject down the side of the vial—this is an extremely sensitive peptide.
- Gently swirl, do not shake.
- Store in the refrigerator (2–8 °C) or freeze in aliquots.
Protocol Overview
- Goal: Anti-inflammatory action, immunomodulation, neuroprotection.
- Schedule: 1–2× daily subcutaneously × 4–8 weeks.
- Note: Associated with the Shoemaker protocol for CIRS.
Dosing Protocol
- Dose: 25–50 mcg per injection.
- Frequency: 1–2×/day subcutaneously.
- Titration: Start with 25 mcg 1×/day, increase to 50 mcg after 2 weeks.
- Cycle: 4–8 weeks.
- Break between cycles: After the cycle, a 4–6 week break is recommended. VIP significantly regulates immunological pathways—use only under medical guidance.
Washout & Cycle Restart
When can I restart?
After the cycle, a 4–6 week break is recommended. VIP significantly regulates immunological pathways—use only under medical guidance.
Minimum wait period: 4 weeks
Storage Instructions
- Powder: −20 °C.
- Reconstituted: 2–8 °C, use within 14 days.
- Ideally, freeze in aliquots to extend shelf-life.
Important Notes
- Extremely sensitive peptide—avoid room temperature.
- May cause hypotension—start low.
- Use under medical guidance, especially in the context of CIRS.
Potential Benefits & Side Effects
Potential Benefits:
- Potent anti-inflammatory action.
- CIRS/mold illness recovery.
- Neuroprotection and vasodilation.
- Improved pulmonary function.
- Circadian rhythm regulation.
Potential Side Effects:
- Hypotension (most common side effect).
- Diarrhea at high doses.
- Injection site redness.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Hypotension & tachycardia
VIP is a potent vasodilator. Can cause significant hypotension, especially with IV administration.
📄 Am J Med 1999References
- VIP in CIRS — Shoemaker RC, et al. Vasoactive intestinal polypeptide as a biomarker of CIRS. Neurotoxicol Teratol. 2013;40:35-44.
View Source - VIP Immunology — Delgado M, et al. VIP and PACAP as immunomodulators. Ann N Y Acad Sci. 2003;1070:51-74.
View Source - VIP Neuroprotection — Gonzalez-Rey E, et al. Therapeutic action of VIP in autoimmune diseases. Endocr Metab Immune Disord Drug Targets. 2007;7(4):272-8.
View Source
Recommended Supplements
Curcumin (Turmeric Extract)
Collagen Peptides
External Sources & Regulatory Status
Regulatory Approvals
Pulmonary hypertension / Sarcoidosis
Phase II clinical trials
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →